You are here: Industry Insights > vertex

News List

Vertex, CRISPR Therapeutics’ sickle cell gene therapy wins PRIME designation pharmatimes
September 27, 2020
Vertex Pharmaceuticals and CRISPR Therapeutics have been awarded a Priority Medicines (PRIME) designation from the European Medicines Agency for their CRISPR/Cas9 gene therapy, designed to treat severe sickle cell disease (SCD).
Moderna and Vertex partner on gene-editing therapies for cystic fibrosis pharmaceutical-technology
September 18, 2020
Moderna has teamed up with Vertex Pharmaceuticals to identify and develop lipid nanoparticles (LNPs) and messenger RNAs (mRNAs) for the delivery of gene-editing therapies to treat cystic fibrosis (CF).
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS europeanpharmaceuticalreview
August 27, 2020
The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis patients, triggering the drug to be accessible on the UK’s National Health Service.
EC approves Vertex’s Kaftrio plus ivacaftor for cystic fibrosis patients pharmaceutical-technology
August 25, 2020
Vertex Pharmaceuticals has secured approval from the European Commission (EC) for the use of Kaftrio (ivacaftor / tezacaftor / elexacaftor) in combination with ivacaftor for the treatment of cystic fibrosis (CF).
EU nod for Vertex CF therapy Kaftrio pharmatimes
August 24, 2020
Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor) has been approved by the European Commission for use in combination with ivacaftor to treat people aged 12 years and older with certain forms of cystic fibrosis.
Vertex and NHS Wales agree on Kaftrio reimbursement pharmatimes
July 23, 2020
People with cystic fibrosis (CF) living in Wales should get speedy access to Vertex' new therapy following its approval by Europe regulators.
Vertex signs 'landmark' deal with NHS for CF therapy pharmatimes
July 01, 2020
Vertex has reached an agreement with NHS England to reimburse its triple combination therapy Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor), should the medicine win European approval.
EU expands reach of Vertex' CF drug Kalydeco pharmatimes
June 11, 2020
EU regulators have expanded the treatment scope of Vertex' Kalydeco (ivacaftor) to include a new subset of young patients with cystic fibrosis (CF).
Vertex to buy Semma Therapeutics for $950m pharmaceutical-technology
September 05, 2019
Vertex Pharmaceuticals will acquire all outstanding shares of biotechnology firm Semma Therapeutics for a cash sum of $950m.
Vertex submits NDA to FDA for triple combination CF drug pharmaceutical-technology
July 24, 2019
Boston-based Vertex Pharmaceuticals has announced it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its triple combination therapy for cystic fibrosis (CF), VX-445 (elexacaftor), tezacaftor and ivacaftor.

Previous page 1 2 3 4 5 6 7 Next page